Life Sciences and Healthcare

What’s driving oncology HTAs in South Korea?

Reimbursement in South Korea depends upon a favorable review by Health Insurance Review Agency  (HIRA), and some therapies may not be reimbursed because of shortcomings from the perspective of HIRA. To help pharma companies plan clinical trials and economic evidence submission in order to achieve favorable access in South Korea, we used the Context Matters […]

Biomarkers have several key roles in clinical trials and precision medicine

Biomarker use in clinicals trials has expanded over the last few decades. Designing a protocol that incorporates biomarkers can reduce trial timelines and increase the chance of success. However, biomarkers remain underutilized for a variety of reasons. Evaluating the trends in biomarker use allows us to monitor the effectiveness of new strategies and identify areas […]

What drives the therapy selection test market?

Clarivate medtech expert Sophia Quraishi reviews key factors driving increased demand for premium-priced therapy selection tests.   Therapy selection tests are a form of liquid biopsy, which involve sequencing substrates isolated from bodily fluids, such as blood, saliva or urine. This approach is less invasive, can be used more often and is more cost effective […]

Patient account management week 2020: recognizing vital contributions!

This week is National Patient Account Management Week, when organizations around the nation honor those staff who have a great influence on healthcare. On October 18, 1989, Congress proclaimed this day of recognition for the healthcare administrative teams who work tirelessly to keep healthcare operations efficient so patients and families have the best experience possible. […]

Six U.S. healthcare policy questions hanging in the balance

Insights provided in this article were developed using data on and analysis of the impact of U.S. policy on healthcare and the pharmaceutical industry by analysts at DRG, part of Clarivate. DRG U.S. Managed Markets Insights provides robust qualitative insights on national, state and MSA level market access dynamics.   Ten years after the passage […]

New era of affordable insulin

Disease management for chronic conditions can be tricky if the cost of medications is unaffordable. Patients, especially the Medicare population, tend to ration the drugs in order to avoid high costs as these require prolonged usage. According to CVS Health, more than 30 million Americans are living with diabetes, one-third of whom do not have […]

Acute respiratory distress syndrome doubles in U.S. during COVID-19

Acute respiratory distress syndrome (ARDS), one of the most severe consequences of COVID-19, is often fatal and may develop in COVID-19 patients already in a critically ill state. To examine the impact of the COVID-19 pandemic on ARDS risk, we analysed the number of patients in the United States making medical claims for ARDS between […]

Reducing readmissions with risk stratification and data analytics: q&a with atrium health

Readmissions are a major problem for many healthcare organizations in the U.S. According to AHRQ’s Healthcare Cost and Utilization Project (click here), the overall readmission rate in the United States was 13.9% in 2016, with the average cost across any type of principal diagnosis being about $14,400. Given this strain on the healthcare industry, it […]

Role of advanced IDNs grows as COVID-19 shifts market dynamics

The COVID-19 pandemic is fundamentally changing healthcare delivery in the United States, from the acceptance of virtual physician visits to payment reform, and from the consolidation of integrated delivery networks to the very survival of independent physician practices. The resultant healthcare environment will be one that is more integrated into daily life with provider reimbursement […]